BioNet and Bio Farma Unite for Vaccine Development Against Infectious Diseases

JAKARTA, Indonesia – June 3, 2025 – BioNet, a Franco-Thai vaccine biotech group, has signed a Memorandum of Understanding (MoU) with PT Bio Farma (Persero), Indonesia’s state-owned vaccine manufacturer, to collaborate on the development and distribution of a combined TdaP vaccine for tetanus, diphtheria, and pertussis.

The memorandum was signed during the state visit of French President Emmanuel Macron to Indonesia. It demonstrates a commitment to improve access to innovative vaccines throughout Southeast Asia. By combining BioNet’s advancements in recombinant pertussis technology with Bio Farma’s extensive manufacturing capabilities, the partnership aims to meet critical immunization needs in the ASEAN region.

Philippe Guillot-Chêne, CEO of BioNet Europe, stated, “This agreement reflects our shared goal to make next-gen vaccines accessible where needed most. By aligning our strengths, BioNet and Bio Farma strengthen the regional health ecosystem and ASEAN’s capacity to respond to current and emerging infectious disease threats.”

The MoU involves cooperation in clinical development, regulatory alignment, and market access. Bio Farma will lead clinical trials and regulatory submissions in Indonesia, while BioNet will manage efforts in other ASEAN countries. The partnership seeks to reduce the time required to introduce vaccines from 10-15 years to less than five.

Yuliana Indriati, Director of Business Development at Bio Farma, remarked, “Through this collaboration, we are reinforcing Indonesia’s commitment to regional vaccine self-sufficiency and innovation. With BioNet’s advanced recombinant pertussis technology and our production capacity, we aim to ensure timely access to TdaP vaccines for Indonesian adolescents, pregnant women, and the elderly. We hope this product will soon be part of our immunization program.”

The TdaP vaccine will combine Bio Farma’s Td and BioNet’s aP antigens, targeting the ASEAN market with an estimated annual need of 10-15 million doses, valued at approximately USD 200 million.

This partnership aligns with President Prabowo Subianto‘s Asta Cita, supporting national self-reliance in economy, food, and energy while enhancing the quality of life and access to affordable healthcare.

About BioNet: BioNet is involved in developing and manufacturing genetically designed vaccines and includes a clinically validated mRNA platform aimed at enhancing pandemic preparedness.

About Bio Farma: PT Bio Farma (Persero) is Indonesia’s largest state-owned pharmaceutical company, managing R&D, manufacturing, and distribution. With over 3.2 billion vaccine doses produced annually, Bio Farma exports to more than 150 countries.